A Review of the Treatment for Multiple Myeloma A panel of experts lead by Dr. Keith Stewart, MB, ChB, discuss the current treatment landscape of multiple myeloma.
Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.
All Peer Exchange Quantifying the Potential Impact of SGLT-2 Inhibitors in Heart Failure Considering Cost Effectiveness in Cardiovascular Risk Reduction Managed Care Consideration for an Emerging Class of Therapy in Anemia of Chronic Kidney Disease Value-based Considerations of CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer Patient Management of Chronic Fibrosing Interstitial Lung Disease With Progressive Phenotype Expanding Treatment Options for Metastatic Breast Cancer COPD Treatment Updates: Impact on Daily Life A Deeper Understanding of Wound Care Understanding the Comorbidities: Psoriasis and Metabolic Syndrome Managing Challenges of Insomnia in Elderly Patients The Challenges and Treatment of Sickle Cell Disease Identifying Secondary Progressive Multiple Sclerosis A Review of the Treatment for Multiple Myeloma Rare Neurological Diseases: Spinal Muscular Atrophy and Huntington's Disease An Introduction of a New Class for the Treatment of Bone Health An Overview of the Value-Based Marketplace The Progression of Type 2 Diabetes and the Treatment Options to Manage It Immunotherapy in the Oncology Care Model Preventive Treatments for Migraines The Use of Biologics for the Treatment of Asthma Improved Outcomes in the Management of Hepatic Encephalopathy Expert Perspectives on Schizophrenia Treatment Approaches and Relapse Prevention Advances and Best Practices in the Utilization of Novel Agents in Metastatic Breast Cancer Oncology Stakeholders Summit, Summer 2018 Emerging Treatment for Migraine Advances in the Treatment of Hyperhidrosis Special Considerations in HIV Management Finding Value in Today's New Insulin Technology in Diabetes Care: From Prevention to Disease Management
Age-Related Macular Degeneration Treatments: Determining Appropriate Use Diabetes Therapy and Cardiovascular Outcomes: An Update Oncology Stakeholders Summit, Spring 2017 Reducing CVD Risk Through Optimal Lipid Management Oncology Stakeholders Summit, Fall 2016 Management Optimization in Atopic Dermatitis Oral Oncolytics: Exploring Challenges in Cost, Adherence, and Management Reducing Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus Oncology Stakeholders Summit, Spring 2016 Diabetes-Related Complications: A Focus on Diabetic Macular Edema Oncology Stakeholders Summit, Fall 2015 Healthcare Reform Stakeholders Summit, Fall 2015 Healthcare Reform Stakeholders Summit, Spring 2015 Oncology Stakeholders Summit, Spring 2015 Oncology Stakeholders Summit 2014 Diabetes and Obesity Management Prostate Cancer Rare Disease Neurological Disorders Immunotherapy Diabetes and Cardiometabolic Health
October 24, 2019 –
The experts share their final thoughts on the progress of treatment options in multiple myeloma.
October 17, 2019 –
Sundar Jagannath, MD, shares his approach to choosing the best treatment plan for patients based on genetic risk in multiple myeloma.
October 17, 2019 –
The key opinion leaders discuss the need for transparency between the National Comprehensive Cancer Network (NCCN) guidelines, payer preference, and real-world patient needs in multiple myeloma.
October 11, 2019 –
The influence of patient cost on choosing an outpatient versus inpatient treatment option are explored in the management of multiple myeloma.
October 11, 2019 –
Sundar Jagannath, MD, emphasizes an individualized treatment approach for relapsed/refractory multiple myeloma.
October 07, 2019 –
Panelists discuss the reimbursement of subcutaneous versus intravenous (IV) dosing and the implications for patients with multiple myeloma.
October 07, 2019 –
A discussion of the Oncology Care Model (OCM) goals to ensure better outcomes for patients with multiple myeloma leads to better cost savings.
September 27, 2019 –
A review of the potential impact of the Oncology Care Model (OCM) on the treatment of multiple myeloma.
September 27, 2019 –
The panel discusses the future of 4-drug combinations for the treatment of multiple myeloma, including the GRIFFIN trial.
September 20, 2019 –
Experts delve into evolving standards of care for patients who are not eligible for transplant in multiple myeloma treatment and discuss the outcomes of the MAIA trial.
